Business Wire

Inotrem Announces €39 Million Series B Financing to Develop First-In-Class Immunology Therapeutics

Share

Inotrem S.A., a biotechnology company specialized in the development of immunotherapies targeting the TREM-1 pathway with potential applications for acute and chronic inflammatory syndromes, announced today a €39 million Series B financing led by Morningside Ventures, joined by Invus with participation from existing investors Andera Partners, Sofinnova Partners and BiomedInvest.

The financing will support the clinical development of Inotrem’s lead drug candidate, nangibotide (an anti-TREM-1 peptide) in a global multicentric Phase IIb trial in septic shock patients (ASTONISH trial) to deliver a meaningful proof of clinical efficacy, as well as its companion diagnostic tool using soluble TREM-1 as a mechanism-based biomarker to select patients that are more likely to respond favorably to treatment. This series B financing will also allow Inotrem to expand its TREM-1 franchise to address chronic inflammatory diseases.

“We are thrilled to have attracted world-class investors from the USA to advance what we believe is a new paradigm in immunotherapy” said Jean-Jacques Garaud, CEO of Inotrem, “This financing validates the potential of our technology platform centered on the TREM-1 pathway and of our lead drug candidate for septic shock, nangibotide, which will be entering a large Phase IIb clinical trial later this year”.

Based on a novel approach of immunomodulation which targets the TREM-1 pathway, Inotrem has developed a proprietary technology platform and leverages its extensive knowledge of the TREM-1 pathway biology to develop programs in several indications with inflammatory syndromes for which there is a major and today unsatisfied therapeutic need. Its lead compound, nangibotide, targets septic shock which is the ultimate complication of sepsis. The incidence of septic shock continuously raises and mortality remains elevated (35%) in developed countries. There is currently no specific mechanism-based therapy approved for this indication. Inotrem’s solution has the potential to become the first mechanism-based treatment for septic shock.

“We have been strongly impressed by Inotrem’s achievements until now and are convinced its approach of immunomodulation which targets the TREM-1 pathway could represent a step change in immunotherapy and bring solutions to patients that today lack effective therapies”, indicated Jason Dinges of Morningside.

In connection with the financing, Dr. Jason Dinges of Morningside will join the Inotrem’s Board of Directors.

Bryan Garnier & Co, the European Growth Investment Bank, supported Inotrem with its fundraising.

About Inotrem
Inotrem S.A. is a biotechnology company specialized in immunotherapy for acute and chronic inflammatory syndromes. The company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses. Through its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, LR12 (nangibotide), with potential applications in a number of therapeutic indications such as septic shock and myocardial infarction. In parallel, Inotrem has also launched another program to develop a new therapeutic modality targeting chronic inflammatory diseases. The company was founded in 2013 by Dr. Jean-Jacques Garaud, a former head of research and early development at the Roche Group, Prof. Sébastien Gibot and Dr. Marc Derive. Inotrem is supported by leading European and North American investors.
www.inotrem.com

About Nangibotide
Nangibotide is the formulation of the active ingredient LR12, which is a 12 amino-acid peptide prepared by chemical synthesis. LR12 is a specific TREM-1 inhibitor, acting as a decoy receptor and interfering in the binding of TREM-1 and its ligand. In preclinical septic shock models, nangibotide was able to restore appropriate inflammatory response, vascular function, and improved animals’ survival post septic shock. Nangibotide in septic shock has been granted the fast track status in September 2019 by the FDA.

ASTONISH Study
The Efficacy, Safety and Tolerability of nangibotide in Patients with Septic Shock (ASTONISH) phase IIb trial is a Randomized, Double-blind, Placebo Controlled Dose Selection Study that will be performed Europe and the US. Four hundred and fifty patients are planned to be included in this study in 48 clinical sites. The study will compare the effect of nangibotide at two different doses versus standard of care. The IND has been cleared by the FDA in August 2019.

Contact information

Media contact for Inotrem
Anne REIN
S&I
anne.rein@strategiesimage.com
+33 6 03 35 92 05

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Alpega TMS Shows Impressive Triple-digit Growth in Expanding SME Segment17.2.2020 18:00:00 EETPress release

Alpega Group, the leading provider of cloud-based, end-to-end transportation and logistics management software in Europe, today announced that new business from its TMS software grew by 100% in the SME segment in 2019. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200217005017/en/ Todd DeLaughter, Alpega Group CEO (Photo: Business Wire) Speaking on the results, Todd DeLaughter, Group CEO for Alpega said: “While the TMS market as a whole is growing in the high teens, we saw particular acceleration in the SME segment as more and more mid-size companies embrace technology to enable business efficiency and reduce cost while lowering carbon emissions. In 2019, we added 83 new clients for our TMS business.” “A big part of this success is down to the flexibility we offer our users. By bringing together the expertise of inet, Transwide and TenderEasy, Alpega TMS is able to cater to businesses dealing with all levels of logistics co

GSMA Board Statement on MWC Barcelona 202017.2.2020 18:00:00 EETPress release

The GSMA Board would like to express its sadness at the unavoidable cancellation of MWC Barcelona 2020. This decision is painful, but we believe the correct one. Health and safety are the priorities of all of the GSMA Board and Mobile Network Operators. Our sincere thoughts are with those affected in China and around the world in these trying times. Our vision at the GSMA is to unlock the power of connectivity so that people, industry and society thrive. MWC is crucial to convene and advance the industry and mobile ecosystem. The mobile industry is committed to harnessing the power of mobile technology and connectivity to transform the lives of billions of people around the world, and we are committed to a great MWC Barcelona 2021. The Board thanks GSMA management and the Host City Parties for their hard work throughout this challenging and unprecedented situation. We look forward to working together again for an even better MWC Barcelona 2021. The GSMA Board is comprised of 25 of the

Mary Kay Inc. Announces Actress, Philanthropist Monique Coleman as First-Ever Pink Changing Lives Honoree17.2.2020 17:00:00 EETPress release

Mary Kay Inc., a long-time leader in global female empowerment, is proud to announce Monique Coleman has been named the brand’s first-ever Pink Changing Lives Honoree. Pink Changing Lives—Mary Kay’s global commitment to celebrate the individuals and organizations that improve women’s and girls’ lives around the world—has supported more than three million women and their families by partnering with over 2,000 organizations and donating over $15 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200217005216/en/ Monique Coleman has been named Mary Kay Inc. first-ever Pink Changing Lives Honoree. (Photo: Mary Kay Inc.) Mary Kay’s Pink Changing Lives cause empowerment program donates funds to organizations focused on supporting cancer research, helping end hunger, protecting survivors from domestic abuse, beautifying communities, and many other programs empowering women and girls. In 2020, Mary Kay created the Pink Changing

ABS, the Royal Canadian Navy, and Defence Research & Development Canada Launch Digital Asset Framework Pilot17.2.2020 16:00:00 EETPress release

ABS today announced it is engaged in a pilot program with the Royal Canadian Navy (RCN) and Defence Research and Development Canada (DRDC) to deliver the ABS Digital Asset Framework for the RCN’s Maritime Coastal Defence Vessels. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200217005014/en/ The HCMS Saskatoon (Photo: Business Wire) The ABS Digital Asset Framework forms the foundation of a broader Conditioned-Based Class program that transforms ship classification from a calendar-based schedule to a condition-based model. The project, which will start with HMCS Saskatoon, will support the RCN’s larger Digital Navy Initiative. “ABS is a leader in delivering condition-based maintenance data services in maritime and offshore applications, and we are proud that the RCN have chosen to work with us on this landmark project,” said Christopher J. Wiernicki, ABS Chairman, President and CEO. “Through our digital programs for commerci

Oasis Is Proud to Announce the Availability of HELIOS 5G, its Latest Release of Secure UICC Operating System17.2.2020 14:15:00 EETPress release

HELIOS 5G proposes enhanced security capabilities to secure critical communication services and respond actively to the greater range of possible threats associated with the wider variety of actors and devices types expected on the fifth generation of mobile network. Among many improvements implemented by Oasis R&D team, HELIOS 5G introduces new features to enable a device to authenticate to the 5G network with increased security and privacy of communications. The network authentication offered by Helios 5G is significantly stronger, due to longer crypto keys and an advanced algorithm. Additionally, the HELIOS OS benefits from a powerful onboard encryption including a SUCI calculator. It anonymizes the subscriber identity, thereby guaranteeing full subscriber privacy. Patrick Cao, Chief Operating Officer, said: “HELIOS 5G is an important milestone in the development history of our Helios SIM and eSIM Operating System. It demonstrates the expertise of our R&D team and confirms our posit

1.86 Customer Minutes Lost (CML) of Electricity per Year in Dubai17.2.2020 13:08:00 EETPress release

Dubai Electricity and Water Authority (DEWA) has achieved a new world record in electricity Customer Minutes Lost (CML) per year. DEWA recorded 1.86 minutes, in Dubai, compared to around 15 minutes recorded by leading electricity companies in the European Union. This is a new addition to DEWA’s record of international achievements in electricity and water services. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200217005093/en/ Dubai Electricity and Water Authority (DEWA) achieves a new world record in electricity Customer Minutes Lost (CML) per year and enhances Dubai’s prosperity. (Photo : AETOSWire). “At DEWA, we work according to the vision and directives of our leadership to provide a robust infrastructure according to the highest international standards. We continuously work to enhance the capacity and efficiency of transmission and distribution networks to provide electricity and water services according to the highes

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom